New AntiVirals 

for Infections 

with Pandemic 

Potential

For infectious disease management and control, vaccines are considered golden countermeasures 
but are not the most adequate tool for mitigating 
the early effects of an outbreak.

Taking the recent COVID-19 pandemic as an example, access to broadly applicable therapeutic antivirals would have had a major impact, decreasing the human toll of the disease, and alleviating the burden carried by health care systems. It is urgent to focus resources and efforts on the development of broad spectrum antiviral drugs against unknown pathogens.

The New AntiVirals for Infections with Pandemic Potential (NAVIPP) consortium aims to strengthen the EU’s readiness and response capacity to viral threats by assembling an international R&D platform for antiviral drug development against pandemic prone pathogens.

navipp by
numbers

0

partners

0

countries

0

years EU-funded
project

0

millions €

NEWS

  • Marburg virus and the ferret model: a step toward better countermeasures

    NAVIPP Scientific Watch Serie Why Marburg matters Marburg virus (MARV) belongs to the filovirus family, the same group as Ebola, and is one of the deadliest pathogens known to humans. With mortality rates reaching up to 90% in some outbreaks, it is considered a major pandemic threat. Yet, progress in developing treatments and vaccines has…

  • New: NAVIPP Brochure Available

    Our new A4 brochure (two-sided) is now available to download! It provides a clear and visual overview of the NAVIPP mission, our dual-track strategy for antiviral discovery and repurposing, and the impact of our consortium on global pandemic preparedness. This concise format is ideal for sharing with partners, stakeholders, and anyone interested in learning more…

  • 🧬 A hidden virus revealed

    NAVIPP Scientific Watch Serie In the quiet bushland of Queensland, Australia, researchers collected urine samples from flying foxes as part of routine Hendra virus surveillance. What they found was unexpected: a completely new member of the henipavirus family, now named Salt Gully virus (SGV). This discovery, recently published in Emerging Infectious Diseases, highlights how pathogens…